Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $164.8 million.

  • Crinetics Pharmaceuticals' Cash from Investing Activities rose 69992.72% to $164.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$425.3 million, marking a year-over-year decrease of 25429.66%. This contributed to the annual value of -$574.8 million for FY2024, which is 18681.62% down from last year.
  • According to the latest figures from Q3 2025, Crinetics Pharmaceuticals' Cash from Investing Activities is $164.8 million, which was up 69992.72% from $38.0 million recorded in Q2 2025.
  • In the past 5 years, Crinetics Pharmaceuticals' Cash from Investing Activities registered a high of $164.8 million during Q3 2025, and its lowest value of -$542.1 million during Q4 2024.
  • Over the past 5 years, Crinetics Pharmaceuticals' median Cash from Investing Activities value was $309000.0 (recorded in 2024), while the average stood at -$46.8 million.
  • Data for Crinetics Pharmaceuticals' Cash from Investing Activities shows a peak YoY increase of 69992.72% (in 2025) and a maximum YoY decrease of 2791909.39% (in 2025) over the last 5 years.
  • Over the past 5 years, Crinetics Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$101.8 million in 2021, then soared by 136.2% to $36.9 million in 2022, then tumbled by 336.91% to -$87.3 million in 2023, then plummeted by 520.89% to -$542.1 million in 2024, then soared by 130.4% to $164.8 million in 2025.
  • Its Cash from Investing Activities was $164.8 million in Q3 2025, compared to $38.0 million in Q2 2025 and -$86.0 million in Q1 2025.